• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

JAK 1 and 2 inhibitor superior to adalimumab in treatment of rheumatoid arthritis: The RA-BEAM trial

byMatthew GrowdonandShaidah Deghan, MSc. MD
February 16, 2017
in Chronic Disease
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Baricitinib, an oral, once-daily inhibitor of JAK1 and JAK2, has shown promise in the treatment of rheumatoid arthritis (RA).

2. In this randomized controlled trial, baricitinib was superior to injectable adalimumab and placebo, in the amelioration of prespecified RA-related symptoms and radiologic outcomes after 12 weeks of follow-up.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The backbone of RA treatment consists of conventional synthetic disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and newer biologic DMARDs such as adalimumab, which targets tumor necrosis factor (TNF). RA-BEAM trial is a multicenter randomized controlled trial that compared baricitinib against placebo and adalimumab. Patients with active RA, received background therapy with methotrexate, and were randomized to receive placebo, baricitinib, or adalimumab. The primary outcome was 20% improvement according to the American College of Rheumatology (ACR20) criteria, which occurred significantly more often in the baricitinib group compared to placebo or adalimumab at week 12. There was also significantly reduced radiographic progression of joint damage at week 24 in the baricitinib group compared to placebo. Both baricitinib and adalimumab were associated with a greater number of adverse events, including infection, compared to placebo; baricitinib in particular was associated with neutropenia and lab abnormalities, such as transient increases in creatinine and cholesterol levels.

This drug-company sponsored trial provides promising evidence in support of a once-daily antirheumatic medication in comparison to accepted therapies including an every-other-week anti-TNF therapy and treatment with methotrexate.

Click to read the study, published today in NEJM

RELATED REPORTS

Zemprocitinib sustained clinical responses through Week 76 in rheumatoid arthritis after inadequate response to biologic therapy

Utility of long-term routine laboratory toxicity monitoring of immunomodulatory drugs in rheumatoid arthritis

Relevant Reading: Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

In-Depth [randomized controlled trial]: This study was conducted over 52 weeks at 281 centers in 26 countries. Participants had RA with an inadequate response to methotrexate patients. A total of 2949 patients were screened for this study and a total of 1305 were treated and qualified for analysis. The ACR20 criteria include a 20% or greater reduction in the number of tender and swollen joints and an improvement of 20% or more in at least three of the following measures: patient assessment of pain, patient global assessment of disease, physical function assessment, and the level of acute-phase reactant.

In the primary analysis, at week 12, the ACR20 response rate for baricitinib was 70% compared to 40% for placebo (p < 0.001). Additionally, baricitinib was found to be noninferior to adalimumab (61%) at week 12 for ACR20 response. In further testing with correction for multiple comparisons, baricitinib was superior to adalimumab for ACR20 response (p = 0.01). In secondary analyses, at week 24, both baricitinib and adalimumab achieved significantly reduced radiographic joint damage compared to placebo, with a suggestion of particular benefit in the adalimumab group.

In safety analyses, rates of serious infections were similar between all three groups (1%, 1%, and <1% respectively for placebo, baricitinib, and adalimumab. There were observed reductions in neutrophil counts, and increases in creatinine and liver enzymes (generally transient) in the baricitinib and adalimumab groups compared to placebo. LDL cholesterol levels increased with baricitinib to a greater extent than adalimumab.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: JAK kinaserheumatoid arthritisTNF
Previous Post

Clinical decision tool may discriminate need for ICU in children with traumatic brain injury and intracranial injury

Next Post

Bariatric surgery superior to medical therapy for diabetes at five-years: The STAMPEDE trial

RelatedReports

The image shows an illustration of a knee joint, accompanied by a representation of an antibody, suggesting a focus on rheumatoid arthritis or psoriatic arthritis and its treatment.
2MM Trial Briefs

Zemprocitinib sustained clinical responses through Week 76 in rheumatoid arthritis after inadequate response to biologic therapy

October 30, 2026
Blood tests collage: a tray of capped sample tubes lying flat, an open benchtop centrifuge and a pipette
Rheumatology

Utility of long-term routine laboratory toxicity monitoring of immunomodulatory drugs in rheumatoid arthritis

August 28, 2025
#VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis
StudyGraphics

#VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis

July 14, 2025
#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk
StudyGraphics

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

December 5, 2024
Next Post

Bariatric surgery superior to medical therapy for diabetes at five-years: The STAMPEDE trial

AAP releases 2017 recommendations for preventive pediatric health care

Periviable infants are becoming more likely to survive without neurodevelopmental impairment

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.